Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
Ontology highlight
ABSTRACT: Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Currently, the standard treatment of glioblastoma includes surgery, radiotherapy, and chemotherapy. Despite aggressive treatment, the median survival is only 15 months. GBM progression and therapeutic resistance are the results of the complex interactions between tumor cells and tumor microenvironment (TME). TME consists of several different cell types, such as stromal cells, endothelial cells and immune cells. Although GBM has the immunologically "cold" characteristic with very little lymphocyte infiltration, the TME of GBM can contain more than 30% of tumor-associated microglia and macrophages (TAMs). TAMs can release cytokines and growth factors to promote tumor proliferation, survival and metastasis prog
SUBMITTER: Wang G
PROVIDER: S-EPMC9363573 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA